Curated News
By: NewsRamp Editorial Staff
May 05, 2025
Pacylex Pharmaceuticals CEO to Present on NMT Inhibitors as ADC Payloads at Summit
TLDR
- Pacylex Pharmaceuticals leads in developing NMTis for cancer, presenting at ADC Payload Summit for potential partnership advantage.
- Zelenirstat, an NMTi, inhibits myristoylation affecting cancer cell growth, validated targets, and oxidative phosphorylation mechanisms.
- Pacylex's NMTis show promise as effective ADC payloads, offering hope for improved cancer treatment outcomes and survival rates.
- Zelenirstat's mechanism of action in killing cancer cells through multiple processes makes it a novel and intriguing potential treatment option.
Impact - Why it Matters
This news highlights the potential breakthrough in cancer treatment using NMT inhibitors as ADC payloads, with zelenirstat showing promising results in Phase 1 trials. The presentation at the summit signifies a step forward in utilizing innovative therapies for hematologic and solid tumor cancers.
Summary
Pacylex Pharmaceuticals Inc., a world leader in N-myristoyltransferase inhibitors for cancer, announced that their CEO, Michael Weickert, will present at the 2nd Annual ADC Payload Summit in Boston. The session will focus on the clinical signals of their oral NMTi, zelenirstat, as a potential ADC payload for cancer treatment.
The company has exclusive rights to 503 NMTis, with zelenirstat showing promising results in Phase 1 trials for lymphoma and solid tumors. The drug has demonstrated efficacy in regression of solid tumors and inhibition of cancer cell growth, making it a potential game-changer in cancer therapy.
Source Statement
This curated news summary relied on this press release disributed by Reportable. Read the source press release here, Pacylex Pharmaceuticals CEO to Present on NMT Inhibitors as ADC Payloads at Summit
